Kim Gustafson, NP
Women's Health · Houston, TXNPI 1164896056
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,099 and has fallen 52.9% since, to $517 in 2025. Among women's health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 195 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mayne Pharma Commercial LLC$760
- Sumitomo Pharma America, Inc.$441
- Pfizer$433
- AbbVie$426
- Myovant Sciences Inc.$307
- Astellas Pharma US Inc$284
- plus $1K from 24 others
What the payments were for
- Food & beverage$4,07498%
- Education$732%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mayne Pharma Commercial LLC | 24 | $760 |
| Sumitomo Pharma America, Inc. | 25 | $441 |
| Pfizer | 29 | $433 |
| AbbVie | 15 | $426 |
| Myovant Sciences Inc. | 13 | $307 |
| Astellas Pharma US Inc | 11 | $284 |
| Currax Pharmaceuticals LLC | 10 | $157 |
| Therapeuticsmd, Inc. | 9 | $151 |
| Boston Scientific | 2 | $120 |
| Millicent US Inc | 7 | $112 |
| Bayer | 4 | $102 |
| Exeltis, USA Inc. | 6 | $100 |
| Coopersurgical, Inc. | 5 | $95 |
| Agile Therapeutics, Inc. | 6 | $88 |
| Exact Sciences | 5 | $83 |
| Avion Pharmaceuticals | 4 | $63 |
| Hologic Sales And Service, LLC | 2 | $52 |
| Organon | 2 | $50 |
| Bausch Health US, LLC | 2 | $50 |
| Evofem Biosciences, Inc. | 3 | $47 |
| Ascend Therapeutics US, LLC | 2 | $42 |
| Innovation Technologies Inc | 1 | $32 |
| Integra Lifesciences Corporation | 1 | $26 |
| Gynesonics, Inc. | 1 | $20 |
| Aspira Women's Health Inc | 1 | $20 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| Mylan Pharmaceuticals Inc. | 1 | $18 |
| Scynexis, Inc. | 1 | $17 |
| Lupin Inc. | 1 | $16 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXTSTELLIS$235
How this compares
$4,147 in reported general payments places this provider in the 95th percentile of 609 women's health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 64 | $3,513 |
| PremarinEstrogens, Conjugated | 13 | $3,165 |
| ProgesteroneProgesterone, Micronized | 37 | $1,978 |
| Estradiol (Twice Weekly)Estradiol | 22 | $1,724 |
| DottiEstradiol | 12 | $1,490 |
| Clobetasol Propionate | 11 | $415 |
| ValacyclovirValacyclovir Hcl | 12 | $290 |
| Fluconazole | 15 | $79 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin | $433 | $3,16513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 609 women's health providers in Texas.
Other women's health in Houston
- Joann St PierreHouston$15K
- Lori WinkHouston$9K
- Andrea DunnHouston$6K
- Erica SmithHouston$4K
- Christie LouisHouston$3K
- Mary UmbleHouston$3K
- Kim OkewunmiHouston$3K
- Kathryn AckermanHouston$2K
- Evelyn TingGrapevine$89K
- Christina TrumanWaco$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.